Aenova France, a wholly-owned subsidiary Aenova Holding, will lease the whole pharmaceutical manufacturing business and the premises at Saint Quentin-Fallavier, Lyon to SkyePharma Group for an initial period of two years, extendable for a further three years.
China-based drug manufacturer Tianyin Pharmaceutical (TPI) is set to start test run at its 250-ton Jiangchuan Macrolide facility (JCM) for good manufacturing practice (GMP) certification process.
Unigene Laboratories, a provider of design, delivery, manufacture and development of peptide-based therapeutics, has entered into a clinical manufacturing agreement with Cara Therapeutics.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced that it has entered into a commercialization, manufacture and supply agreement with Teva Pharmaceutical USA, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd., to manufacture and market Gemcitabine HCI for Injection. Under the terms of the agreement APP has been granted a license to market Gemcitabine HCI for Injection in 200 mg and 1 g single dose vials during the 180 day Hatch Waxman exclusivity period. APP plans to launch Gemcitabine immediately.
The Spanish Medicines Agency has given Investigational Medicinal Products (IMP) License to Midatech Biogune to manufacture clinical grade nanoparticles at its Bilbao manufacturing facility, Spain.
Pharmatek Laboratories, a pharmaceutical chemistry development company, has added spray drying to its drug formulation and manufacturing capabilities.Pharmatek has acquired a Buchi B-290 Mini Spray Dryer for formulation feasibility studies and small-scale clinical manufacture.